Mandate

Vinge advises the founders of NOOS Digital in connection with the merger with Rocket Revenue and 56K Digital

November 04, 2025 M&A

Following the recent merger between Rocket Revenue and 56K Digital, the group now takes its next step by joining forces with NOOS Digital. The three companies will integrate into one of the Nordic region’s most comprehensive partners for digital transformation and business acceleration.

NOOS Digital has a strong track record as a strategic advisor to leading Nordic retailers and is one of the region’s fastest growing and most forward-thinking management consultancies. Combined with 56K’s technology-driven digital marketing expertise and Rocket Revenue’s creative, performance-centric execution, the new entity forms a truly holistic partner for modern commerce looking to drive profitable growth. With nearly 100 specialists across strategy, data, performance and creative – and offices in Stockholm, Gothenburg, Borås and Helsingborg – the group aims to redefine what a modern digital consultancy can be by combining the analytical depth of consulting with the agility of a top-tier creative performance agency.

Vinge, through Viktor Ramhult, advised the founders of NOOS Digital in connection with the merger.

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026